Table 1.

Baseline characteristics

Variable	MESA	DHS
N	6621	2202
Age	62 [53, 70]	44 [37, 52]
Male	47%	44%
Race/ethnicity
White	38%	34%
Black	27%	47%
Hispanic	22%	16%
Asian/Other	12%	2%
BMI	27.6 [24.6, 31.2]	28.2 [24.6, 32.4]
Hypertension	45%	31%
Medication for hypertension	37%	19%
SBP	124 [112, 140]	121 [112, 133]
DBP	72 [65, 79]	77 [71, 84]
Diabetes	13%	9%
Current smoker	13%	27%
Hypercholesterolemia	37%	13%
Statin medication	15%	6%
Lipids
Total Cholesterol	192 [170, 215]	180 [157, 205]
LDL Cholesterol	116 [96, 136]	106 [84, 129]
HDL Cholesterol	48 [40, 59]	48 [40, 58]
Triglycerides	111 [78, 161]	97 [69, 146]
Test Results
ECG-LVH	9%	9%
CAC, Agatston U	0 [0, 86.5]	0.5 [0, 4.3]
CAC > 10 U	42%	19%
NT-proBNP, pg/mL	53.0 [24.0, 107.7]	27.4 [12.7, 56.0]
NT-proBNP ≥100 pg/mL	27%	11%
Hs-cTnT, ng/L	4.4 [3.0, 7.5]	1.5 [1.5, 1.5]
hs-cTnT ≥ 5 ng/L	44%	14%
Hs-CRP, mg/L	1.9 [0.8, 4.2]	2.7 [1.1, 6.2]
Hs-CRP ≥ 3 mg/L	36%	45%
Endpoints
Global CVD	1026 (15.5%)	179 (8.1%)
ASCVD	486 (7.3%)	96 (4.4%)
CHD	314 (4.7%)	61 (2.8%)
CHF	252 (3.8%)	28 (1.3%)
All cause death	806 (12.2%)	94 (4.3%)
CV death	183 (2.8%)	46 (2.1%)

Continuous variables are presented as median [interquartile range]. BMI=body mass index; SBP=systolic blood pressure; DBP=diastolic blood pressure; LDL=low density lipoprotein, HDL=high density lipoprotein; ECG=electrocardiogram; LVH=left ventricular hypertrophy; CAC=coronary artery calcium score; NT-proBNP=N-terminal prohormone of B-type natriuretic peptide; hs-cTnT=high sensitivity cardiac troponin T. CVD=cardiovascular disease; ASCVD=atherosclerotic CVD, CHD=coronary heart disease; CHF=congestive heart failure; CV=cardiovascular